In a study of adjuvant PD‐1 inhibitor therapy for Stage III melanoma, there were 23 patients (20%) that harbored BRAF mutation, 21 patients (18.3%) harbored NRAS mutation, and 59 patients (51.3%) with BRAF/NRAS wild‐type [414]. This evidence concerns the gene NRAS and melanoma.